Cboe AU - Delayed Quote AUD

Acrux Limited (ACR.XA)

0.0600 +0.0010 (+1.69%)
At close: 3:59 PM GMT+10

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus CEO, MD & Executive Director 517.86k -- 1966
Ms. Joanna Johnson B.E., BEc, ICAA CFO & Company Secretary 273.93k -- --

Acrux Limited

103-113, Stanley Street
West Melbourne, VIC 3003
Australia
61 3 8379 0100 https://www.acrux.com.au

Description

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Corporate Governance

Acrux Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events